AstraZeneca’s DKD pipeline highlights potential to differentiate in kidney disease space, says analyst

19 February 2024

UK pharma major AstraZeneca (LSE: AZN) has recently revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD) in response to Phase IIb efficacy data.

The objective of the Phase IIb study was to evaluate the safety and efficacy of tozorakimab, an anti-interleukin (IL)-33 monoclonal antibody, in subjects with DKD. Despite this setback, AstraZeneca is looking to differentiate in the DKD space with its pipeline drug, zibotentan. If approved, having another treatment option could be of high value to physicians looking to find an optimal treatment of choice for individuals with DKD, says sector analytics company GlobalData.

“According to key opinion leaders (KOLs) interviewed by GlobalData, unmet needs in the kidney disease space include next-generation therapies with alternate mechanisms of action and enhanced clinical profiles,” commented GlobalData’s senior pharma analyst Kajal Jaddoo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK